University College London
London, United Kingdom
Team details appear once the team leader joins.
Is this your team? Claim it
Epilepsy
FollowWhat is new in Epilepsy research, which clinical trials are open, and who works on it. From public registries and PubMed, with the source and date of every fact.
Cure status
- 0.5mg elsunersenPhase 3 · NCT07019922
- 1.0mg/kg/day PRAX-562Phase 3 · NCT07010471
- 1.5mg/kg/day PRAX-562Phase 3 · NCT07010471
- 1mg elsunersenPhase 3 · NCT07019922
- 20 mg/day vormatrogine for 12 weeksPhase 3 · NCT07505004
- 30 mg/day vormatrogine for 12 weeksPhase 3 · NCT07505004
- 40 mg/day vormatrogine for 12 weeksPhase 3 · NCT07505004
- Absence epilepsy medicationsPhase 3 · NCT04274179
- AnakinraPhase 3 · NCT07281027
- BiperidenPhase 3 · NCT04945213
- BrivaracetamPhase 3 · NCT04715646
- Brivaracetam Film-coated tabletPhase 3 · NCT06315322
- Brivaracetam oral solutionPhase 3 · NCT06315322
- Cannabidiol (CBD) oral solutionPhase 3 · NCT07668856
- CarisbamatePhase 3 · NCT05219617
- CenobamatePhase 3 · NCT06352723 · NCT06579573 · NCT06590896
- Cenobamate (syrup) for 2 to < 18 year oldsPhase 3 · NCT07594158
- Cenobamate (tablet) for 12 to < 18 year oldsPhase 3 · NCT07594158
- Clemizole HClPhase 3 · NCT05066217 · NCT04462770
- EverolimusPhase 3 · NCT07095933 · NCT02962414
- FenfluraminePhase 3 · NCT05064878
- Fentanyl (IV)Phase 3 · NCT07165262
- Ketamine (0.5 mg/kg)Phase 3 · NCT07165262
- LemborexantPhase 3 · NCT06262594
- LevetiracetamPhase 3 · NCT07490769 · NCT07239115
- Levetiracetam 500mgPhase 3 · NCT07234695
- LP352Phase 3 · NCT06719141 · NCT06908226 · NCT06660394
- NRTX-1001Phase 3 · NCT06422923 · NCT05135091
- RAP-219Phase 3 · NCT07563881 · NCT07219407 · NCT07594119
- TocilizumabPhase 3 · NCT07281027
- Treatment of edaravone dexborneol sublingual tablets containin edaravone 30 mg plus borneol 6 mg, twice daily (with an interval of ≥6 hours between doses) for three months.Phase 3 · NCT07604350
- vormatroginePhase 3 · NCT07287163
- XEN1101Phase 3 · NCT05667142 · NCT03796962 · NCT05718817 · NCT05716100
- YCJ-01 Full Spectrum cannbis ExtractPhase 3 · NCT07403266
- zorevunersenPhase 3 · NCT06872125
- BHV-7000Phase 2/3 · NCT06443463 · NCT06309966 · NCT06132893
- Exogenous ketone esterPhase 2/3 · NCT05670847 · NCT05674552
- JZP926 capsulePhase 2/3 · NCT07723963
- PRAX-562Phase 2/3 · NCT05818553
- RapamycinPhase 2/3 · NCT04987463
- VigabatrinPhase 2/3 · NCT04987463
- 30mg PRAX-628Phase 2 · NCT06908356
- 5-ALA (Gliolan)Phase 2 · NCT07657975
- ABS-1230Phase 2 · NCT07600736 · NCT07156201
- AV078Phase 2 · NCT07680322
- BMB-101Phase 2 · NCT06401538
- Cannabidiol oral solutionPhase 2 · NCT05803434
- CB03-154Phase 2 · NCT07238868
- CBD CHEPhase 2 · NCT07023744
- CBD IsolatePhase 2 · NCT07023744
- Celecoxib 200mgPhase 2 · NCT05637086
- FerumoxytolPhase 2 · NCT06483061
- Glycerol PhenylbutyratePhase 2 · NCT07847918
- KetaminePhase 2 · NCT07768618 · NCT04861051
- Pentoxifylline 400 MGPhase 2 · NCT05637086
- Perampanel Oral SuspensionPhase 2 · NCT04015141
- Perampanel TabletPhase 2 · NCT04015141
- PhenytoinPhase 2 · NCT05637086
- ProbenecidPhase 2 · NCT07318870
- RNS SystemPhase 2 · NCT05339126
- SirolimusPhase 2 · NCT06719791 · NCT05104983
- SPN-817Phase 2 · NCT07141329 · NCT05518578 · NCT06798896
- Test drug CB03-154 10mg groupPhase 2 · NCT06612775
- Test drug CB03-154 20mg groupPhase 2 · NCT06612775
- Test drug CB03-154 5mg groupPhase 2 · NCT06612775
- zorevunersen (STK-001)Phase 2 · NCT04740476
- AAV9-hSyn1-miGRIK2Phase 1/2 · NCT06063850
- Antisense oligonucleotide treatment (ASO)Phase 1/2 · NCT07363603
- Atorvastatin 10mgPhase 1/2 · NCT06369571
- AyahuascaPhase 1/2 · NCT07747324
- CBD: GT4 Transdermal Delivery SystemPhase 1/2 · NCT06738732
- ETX101Phase 1/2 · NCT05419492 · NCT06112275 · NCT06283212
- GabapentinPhase 1/2 · NCT05664464
- ION337Phase 1/2 · NCT07531745
- lentiviral gene therapyPhase 1/2 · NCT04601974
- MemantinePhase 1/2 · NCT05664464
- NaviFUS SystemPhase 1/2 · NCT06388707
- PRAX-222 - Fixed DosesPhase 1/2 · NCT05737784
- PRAX-222 - Initial Ascending DosesPhase 1/2 · NCT05737784
- PRAX-222 - Initial DosePhase 1/2 · NCT05737784
- PRAX-222 - Optional Ascending DosesPhase 1/2 · NCT05737784
- RadiotherapyPhase 1/2 · NCT05664464
- SulfasalazinePhase 1/2 · NCT05664464
- TemozolomidePhase 1/2 · NCT05664464
- [18F]DPA-714 Positron Emission Tomography ScanPhase 1 · NCT03999164
- GadoliniumPhase 1 · NCT02531880
- iQ-007Phase 1 · NCT06899230
- Magnetic Resonance Imaging-guided Focused Ultrasound Ablation (MRgFUSA)Phase 1 · NCT05032105
- MangafodipirPhase 1 · NCT02531880
- MR-guided Focused Ultrasound TherapyPhase 1 · NCT07249190
- OmeprazolePhase 1 · NCT07156201
- SIF001Phase 1 · NCT07051629
- UX-GIP001Phase 1 · NCT07244328 · NCT07572812
- VoriconazolePhase 1 · NCT07156201
- 2-phenylethanol rose scentEarly phase 1 · NCT07116421
- COBENFY KarXT (50/20 mg)Early phase 1 · NCT07228338
- Cobenfy KarXT pill (50/20 mg)Early phase 1 · NCT07721272
- ControlEarly phase 1 · NCT07228338
- EEG Record onlyEarly phase 1 · NCT07821697
- Glycerol Phenylbutyrate 1100 MG/ML [Ravicti]Early phase 1 · NCT04937062
- Preventative Medication (PM)Early phase 1 · NCT07012148
- PropranololEarly phase 1 · NCT06719804
- RC001 injection-Dose Escalation CohortEarly phase 1 · NCT07675746
- RC001 injection-Fixed Dose CohortEarly phase 1 · NCT07675746
- Scopolamine (0.4mg)Early phase 1 · NCT05594017
- UNEEG SubQ device, seizure forecasts, nasal diazepamEarly phase 1 · NCT07012148
Closest to patients
- Exogenous Ketone Esters for Drug Resistant EpilepsyExogenous Ketone Esters for Drug Resistant EpilepsyDepartment of Pediatrics at Sohag University Hospital · Sohag, EgyptPhase 2/3Primary completion 2025
- Exogenous Ketone Esters for Refractory Status EpilepticsExogenous Ketone Esters for Refractory Status EpilepticsDepartment of Pediatrics at Sohag University Hospital · Sohag, EgyptPhase 2/3Primary completion 2025
- A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)Praxis Research Site · Tel HaShomer, Israel + 7 more hospitalsPhase 2/3Primary completion 2025
Let us optimize your content
Apply for experimental treatment or a research study
The trial team decides who can take part; your doctor can help you ask.
Distance is calculated in your browser. Your city is not sent to us.
Loading trial sites…
Latest news
Results, new trials and publications, newest first. Every item links to its source.
Results and new studies, newest first, in plain words.
Plain-language summary pending. Original title shown.
Publication
Stepwise administration of de novo ketogenic parenteral nutrition for refractory epilepsy during prolonged bowel rest following duodenal perforation.
Stepwise administration of de novo ketogenic parenteral nutrition for refractory epilepsy during prolonged bowel rest following duodenal perforation.
JPGN reports
PubMed · PMID 42964628Publication
First-trimester trace-element profiles in pregnant women with epilepsy: An exploratory prospective association between selenium and subsequent seizure recurrence.
First-trimester trace-element profiles in pregnant women with epilepsy: An exploratory prospective association between selenium and subsequent seizure recurrence.
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
PubMed · PMID 42958972Publication
Response Surface Methodology-Guided Development of Hot-Melt-Extruded Cannabidiol Solid Self-Emulsifying Drug Delivery Systems for Enhanced Drug Release and Stability.
Response Surface Methodology-Guided Development of Hot-Melt-Extruded Cannabidiol Solid Self-Emulsifying Drug Delivery Systems for Enhanced Drug Release and Stability.
Pharmaceutics
PubMed · PMID 42942832Publication
A prospective, open-label randomized controlled trial: efficacy of prednisolone with vitamin B12 versus prednisolone in children with infantile epileptic spasms syndrome.
A prospective, open-label randomized controlled trial: efficacy of prednisolone with vitamin B12 versus prednisolone in children with infantile epileptic spasms syndrome.
Seizure
PubMed · PMID 42950657
Find fellow researchers
Groups with active Epilepsy work.
Inserm
Paris, France
Team details appear once the team leader joins.
Is this your team? Claim it
Harvard University
Cambridge, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Capital Medical University
Beijing, China
Team details appear once the team leader joins.
Is this your team? Claim it
The University of Melbourne
Melbourne, Australia
Team details appear once the team leader joins.
Is this your team? Claim it
UCL Queen Square Institute of Neurology
London, United Kingdom
Team details appear once the team leader joins.
Is this your team? Claim it
Mayo Clinic
Rochester, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Centre National de la Recherche Scientifique
Paris, France
Team details appear once the team leader joins.
Is this your team? Claim it
University of Pennsylvania
Philadelphia, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Boston Children's Hospital
Boston, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Johns Hopkins University
Baltimore, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Monash University
Melbourne, Australia
Team details appear once the team leader joins.
Is this your team? Claim it